Patents | Published:

Prior art considerations when patenting DNA sequences

Nature Biotechnology volume 14, pages 13091310 (1996) | Download Citation

Subjects

Prior disclosure of corresponding protein sequences or uncharacterized DNA sequences may impact your chances to patent a newly discovered DNA.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Amgen Inc. v. Chugai Pharmaceutical Co. , Ltd., 9 USPQ2d 1833 (D. Mass. 1989); 18 USPQ2d 1016 (Fed. Cir. 1991).

  2. 2.

    In re Bell 26 USPQ2d 1529 (Fed. Cir. 1993).

  3. 3.

    In re Deuel 34 USPQ2d 1210 (Fed. Cir. 1995).

  4. 4.

    In re Deuel, 34 USPQ2d at 1215.

Download references

Author information

Affiliations

  1. Patent attorney at Novo Nordisk of North America, 405 Lexington Ave., Suite 6400, New York, NY 10017 (CHAlaw@aol.com).

    • Cheryl H. Agris

Authors

  1. Search for Cheryl H. Agris in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1096-1309